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CDK1 and CDK2 regulate NICD1 turnover and the
periodicity of the segmentation clock
Francesca Anna Carrieri1, Philip J Murray2, Dimitrinka Ditsova1, Margaret Ashley Ferris3, Paul Davies4
& Jacqueline Kim Dale1,*
Abstract
All vertebrates share a segmented body axis. Segments form from
the rostral end of the presomitic mesoderm (PSM) with a periodic-
ity that is regulated by the segmentation clock. The segmentation
clock is a molecular oscillator that exhibits dynamic clock gene
expression across the PSM with a periodicity that matches somite
formation. Notch signalling is crucial to this process. Altering
Notch intracellular domain (NICD) stability affects both the clock
period and somite size. However, the mechanism by which NICD
stability is regulated in this context is unclear. We identified a
highly conserved site crucial for NICD recognition by the SCF E3
ligase, which targets NICD for degradation. We demonstrate both
CDK1 and CDK2 can phosphorylate NICD in the domain where this
crucial residue lies and that NICD levels vary in a cell cycle-depen-
dent manner. Inhibiting CDK1 or CDK2 activity increases NICD
levels both in vitro and in vivo, leading to a delay of clock gene
oscillations and an increase in somite size.
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Introduction
Segmentation, a process which occurs early during vertebrate body
plan formation, generates repeated segments (or somites) that later
give rise to the vertebral column, most skeletal musculature and
dermis [1,2].
During somitogenesis, pairs of somites bud off the rostral end of
the unsegmented presomitic mesoderm (PSM) with a periodicity
that is species specific. The periodicity of segment formation is regu-
lated by a molecular oscillator, known as the somitogenesis clock,
which drives oscillatory gene expression within the PSM tissue from
which somites are derived [2–4].
The genes that exhibit oscillatory PSM expression are termed
clock genes and are targets of the Notch, Wnt and FGF pathways
[5,6]. Aberrant somitogenesis leads to severe segmentation and
skeletal defects [7]. In humans, defects in segmentation lead to
congenital scoliosis (CS), with an infant mortality rate of 50% that
comprises many vertebral skeletal and muscular pathologies,
including the family of spondylocostal dysostoses (SCD). For CS,
while the aetiology is unclear, linkage analyses have shown muta-
tions in six genes (DLL3, MESP2, LFNG, HES7, TBX6 and RIPPLY2)
lead to familial forms of SCD [8]. Significantly, four of these are
components of the Notch pathway (DLL3, MESP2, LFNG, HES7),
which plays multiple roles during segmentation. Notch is crucial to
the segmentation process in mice, since in the absence of Notch
signalling, the segmentation clock stops and no somites form [9].
On a single cell level in the PSM, oscillatory clock gene expression
is established through positive and negative feedback loops of unsta-
ble clock gene products, which potentiate or inhibit the pathway that
activates them. Synchronization of clock gene oscillations between
neighbouring cells is reliant on Notch signalling [10–13]. Mathemati-
cal models predict the period of clock gene oscillations can be approx-
imated as a sum of the delays involved in transcription, splicing,
translation and transport of clock gene products, and in particular
through the regulation of the half-lives of both mRNA and protein of
unstable regulators [14–17]. Progress has been made in demonstrat-
ing the role of transcription and splicing delays in setting the clock
period. However, with the respect to the half-life of clock components
this has been shown to play an important role in clock function [18–
20], but little experimental work investigating whether stability of
clock components affects clock period has been performed.
Most studies addressing the molecular mechanisms regulating
the periodicity of clock gene oscillations have focused on the role of
Notch signalling components [10,19,21–25].
Notch is one of the major highly conserved signalling pathways
that regulate cell–cell communication, which involves gene regula-
tion mechanisms that control multiple processes during develop-
ment and adult life [26–33].
Upon extracellular ligand binding, Notch transmembrane recep-
tors are cleaved, releasing the intracellular domain (NICD) that
translocates to the nucleus to regulate expression of specific
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developmental gene cohorts [32–34]. NICD is highly labile, and
phosphorylation-dependent turnover acts to restrict Notch signalling
[35–37].
Most canonical Notch activity relies on this regulation of NICD
turnover. Moreover, aberrant NICD turnover contributes to numer-
ous cancers and diseases [26,30,38–43]. Despite the multiple
impacts of NICD turnover in both development and disease, the
molecular mechanism regulating this turnover remains largely
uncharacterized. The stability of NICD and therefore duration of the
Notch signal is regulated by phosphorylation of the C-Terminal
PEST domain which leads to subsequent recruitment of FBXW7,
F-Box and WD Repeat Domain Containing 7 (a key component of
the SCFSel10/FBXW7 E3 ubiquitin ligase complex) [35–38,44–49]. Ulti-
mately, this leads NICD to ubiquitylation and proteasomal degrada-
tion [44,50–53].
However, the molecular details of NICD degradation mediated by
FBXW7 are not well understood.
A recent study combining experimental and computational biol-
ogy demonstrated changes in NICD stability dramatically affects the
chick and mouse somitogenesis clock period, which in turn affects
somite size. In this study, a pharmacological approach was used to
demonstrate that culturing chick/mouse PSM explants with broad
specificity inhibitors leads to elevated levels and a prolonged NICD
half-life and phase shifted clock oscillation patterns at a tissue level,
leading to larger segments. Furthermore, reducing NICD production
in this assay rescues these effects [21]. These results imply potential
coupling between NICD degradation and the segmentation clock.
However, the molecular mechanism of action of the inhibitors was
not explored and leaves open the question of whether this coupling
is a general or conserved mechanism.
In this manuscript, we identify the phosphorylated residues
within human NICD. We demonstrate that purified recombinant
Cyclin-dependent kinase 1 (CDK1) and Cyclin-dependent kinase 2
(CDK2) phosphorylate NICD within the PEST domain. A point muta-
tion affecting a conserved serine residue within this CDK substrate
domain of the NICD PEST motif prevents NICD interaction with
endogenous FBXW7. Strikingly, we show that NICD levels fluctuate
in a cell cycle-dependent manner correlating inversely with high
levels of CDK1/2 activity. Lastly, we demonstrate, using a variety of
assays, that inhibition of CDK1 or CDK2 activity leads to increased
levels of NICD in vitro and in vivo and delays the mouse somito-
genesis clock and somite formation, leading to larger somites.
Using a mathematical model, we show that the experimental
observations made in cell lines and PSM tissue can be explained in
a single theoretical framework that couples the cell cycle to NICD
degradation.
Results
Roscovitine, DRB and XAV939 increase NICD levels in HEK293, iPS,
mES and IMR90 cells
A study using broad-range inhibitors demonstrated that the stability
and turnover of NICD is linked to the regulation of the pace of the
segmentation clock across the PSM in chick and mice embryos [21].
However, this study did not define the molecular mechanism of
action of the inhibitors.
It has been reported that direct phosphorylation of NICD in its
PEST domain enhances its turnover and thus degradation [35–37].
In order to identify which kinases are involved in NICD phosphory-
lation and which residues in the NICD PEST domain are phosphory-
lated rendering NICD susceptible to degradation, we employed a
cellular model due to the limiting quantity of material available
using embryonic cell lysates.
First, we used the same inhibitors as Wiedermann et al [21] and
thus investigated if Roscovitine, DRB and XAV939 elicit the same
effect upon NICD levels in a variety of cell culture models, namely
HEK293 (human embryonic kidney), iPS (induced pluripotent stem
cells), mES (mouse embryonic stem cells) and IMR90 (human
Caucasian fetal lung fibroblast) cells.
Roscovitine is a small molecule belonging to the family of
purines. It inhibits Cyclin-dependent kinases (CDKs) through direct
competition with ATP for binding at the ATP-binding site of CDKs
[54,55]. DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole) also
inhibits CDKs, particularly CDK7 and 9 [56,57]. XAV939 is a Wnt
inhibitor that stimulates b-catenin degradation by stabilizing axin
through inhibition of the enzymes tankyrase 1 and 2 [58].
HEK293, iPS, mES or IMR90 cells treated for 3 h with each of the
three inhibitors at the same concentrations used in embryonic lysate
studies [21] led to an increase in NICD levels compared to control
cells cultured in the presence of DMSO (Figs 1A–D and EV1A–C). In
control conditions, NICD was not easily detectable due to its very
short half-life. Quantification of the density of Western blot bands in
at least three independent experiments confirmed that the increase
in NICD levels was statistically significant after treatment with
Roscovitine, DRB and XAV939, as shown in Figs 1B and D, and
EV1B. Two other inhibitors were used as positive and negative
controls for the assay. LY411575 is a c-secretase inhibitor that
prevents Notch1 cleavage and thus inhibits activation of target gene
expression [59,60]. As expected, LY411575 treatment significantly
reduced NICD levels (Figs 1A–D and EV1A–C). Phosphorylation of
the C-Terminal PEST domain of NICD leads to recruitment of
FBXW7 and thus to NICD ubiquitylation and proteasomal degrada-
tion [35–38,44,46–48]. When E3 ligase activity is reduced with the
NEDDylation inhibitor MLN4924 [61], NICD levels increase, since
NICD degradation is stopped in the presence of this compound
(Figs 1A–D and EV1A–C).
Interestingly, we were able to detect two distinct bands by
Western blot with the NICD antibody, particularly when cells were
treated with MLN4924. We hypothesized this reflected the pres-
ence of non-phospho and phospho-NICD species. To test this
hypothesis, we treated MLN4924-treated lysates with k phos-
phatase, which abrogated the appearance of the higher band by
Western blot with the NICD antibody (Fig 1A and C). These data
demonstrate that the higher band detected corresponds to a phos-
phorylated form of NICD. It is noteworthy that quantification of
NICD levels following MLN4924 and k phosphatase treatment
reveals that they are not significantly different to NICD levels in
DMSO-treated cells (Fig 1B and D), albeit that NICD levels can
vary considerably in DMSO-treated lysates. This suggests an addi-
tional scientific possibility, which is that when all phosphorylation
modifications are removed upon k phosphatase treatment, NICD is
also very unstable and degraded by a mechanism other than SCF
E3 ligase, indicating that some phosphorylation events may actu-
ally stabilize NICD.
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Figure 1. Endogenous NICD levels increase in HEK293 cells following treatment with Roscovitine, DRB and XAV939.
A HEK293 cells were treated for 3 h with 150 nM of LY411575, 1 lM of MLN4924, 10 lM of Roscovitine, 10 lM DRB or 10 lM XAV939. DMSO served as vehicle control.
Transfection with pCS2-NICD vector served as positive control. Western blot analysis reveals that NICD levels were increased upon treatment with Roscovitine, DRB,
XAV939 or MLN4924. NICD is undetectable following LY411575 treatment. NICD antibody detects a doublet following inhibitor treatment, and the top band
disappears following k phosphatase treatment indicating that this top band is a phosphorylated isoform. b-Actin served as loading control.
B Quantification of the density of Western blot bands in (A) using ImageJ software. Data are expressed as fold changes compared to DMSO treatment. All data represent
the mean  SEM from three independent experiments. One-way ANOVA analysis, followed by Dunnett’s test, was performed with **P ≤ 0.01 and ns = not
significant.
C iPS cells were treated for 3 h with 150 nM of LY411575, 1 lM of MLN4924, 10 lM of Roscovitine, 10 lM DRB or 10 lM XAV939. DMSO has been used as vehicle
control. Western blot analysis reveals that NICD levels were increased upon treatment with Roscovitine, DRB, XAV939 or MLN4924. NICD is undetectable following
LY411575 treatment. NICD antibody detects a doublet following Inhibitor treatment and the top band disappears following k phosphatase treatment indicative that
this top band is a phosphorylated isoform. b-Actin served as loading control.
D Quantification of the density of Western blot bands in (C) using ImageJ software. Data are expressed as fold changes compared to DMSO treatment. All data represent
the mean  SEM from three independent experiments. One-way ANOVA analysis, followed by Dunnett’s test, was performed with *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
and ns = not significant.
E HEK293 cells were treated with the same inhibitors as described in (A). NICD phosphorylation status was analysed by a Phos-tag assay. DMSO served as vehicle
control. NICD phosphorylation profile varies following Roscovitine, DRB, XAV939 or MLN4924 treatment. Following k phosphatase treatment, none of the high
molecular weight bands are visible indicating they are all phosphorylated isoforms.
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In order to determine whether the increased levels of NICD were
due to increased NICD production and/or increased NICD stability,
we exposed HEK293 cells to LY411575 treatment for the last hour of
culture, thereby inhibiting the production of new NICD. Under
control conditions with LY411575 treatment in the last hour, NICD
levels are very low (Appendix Fig S1A, lane 1). However, despite
LY411575 treatment in the last hour, cells cultured in the presence
of small molecule inhibitors showed increased levels of NICD
compared to the control, indicating that the increase in NICD levels
is not due to increased NICD production, but to an increased stabil-
ity (Appendix Fig S1A).
Taken together, these results show that exposure to this group of
inhibitors leads to increased levels of NICD in a variety of cell lines,
in the same way that they do in the mouse and chicken PSM tissue,
suggesting they regulate a conserved mechanism leading to
increased NICD levels and reduced NICD turnover.
Phos-tag analysis following Roscovitine, DRB and XAV939
treatment reveals a variety of NICD phospho-species
In order to investigate whether this selection of small molecule inhi-
bitors has different effects on NICD phosphorylation, we treated
HEK293 cells with the inhibitors and performed a Phos-tag assay
[62]. This modified Western blot assay allows simultaneous visual-
ization of different phosphorylated isoforms of a given protein of
interest, as a result of their different migration speeds. Following
MLN4924 treatment, a variety of bands indicative of different phos-
pho-species of NICD was observed (Fig 1E and Appendix Fig S1B).
Given that very few bands are present in the control sample
(DMSO, Fig 1E), the bands detected after MLN4924 treatment are
likely to be very labile isoforms of the NICD peptide, which are
rapidly degraded in the DMSO sample. In contrast, when whole-cell
lysate was treated with both MLN4924 and k phosphatase, only one
band, of the lowest molecular weight, was detectable, further
supporting the notion that the ladder of bands obtained upon
MLN4924 treatment reflects a variety of unstable phosphorylated
NICD isoforms, which is completely depleted in the presence of k
phosphatase (Fig 1E). As expected from data showing NICD levels
are increased after inhibitor treatment (Fig 1A–D), all three inhibi-
tors Roscovitine, DRB and XAV939 cause a noticeable increase in
the number and intensity of bands compared to control cells.
However, compared to the effect seen with MLN4924, Phos-tag
technology reveals Roscovitine, DRB and XAV939 have a reduced
number of phospho-bands as compared to MLN4924, indicative of
the fact these inhibitors act to reduce NICD phosphorylation. More-
over, each of the inhibitors presents a distinct profile of NICD phos-
pho-species. These data suggest that NICD is targeted by several
kinases and/or phosphorylation events, which are differentially
sensitive to these inhibitors (Fig 1E and Appendix Fig S1B). In each
case, however, the highest molecular bands were no longer visible.
Concomitant treatment with various inhibitors together with
MLN4924 followed by Phos-tag analysis demonstrates the inhibitors
are actually preventing the production of the uppermost phosphory-
lated band of NICD that accumulates after MLN4924 inhibition
alone (Appendix Fig S1B). It is possible that the multiple phospho-
rylation bands are indicative of unique events, some of which may
reflect priming phosphorylation events that facilitate or increase the
efficiency of secondary phosphorylation events, which then act as
phospho-degron signals to recruit E3 ligases that target NICD for
degradation.
NICD-FBXW7 interact at the endogenous levels in HEK293 cells,
in a phosphorylation-dependent manner
The involvement of the F-box protein component of the SCF E3
ligase complex, FBXW7, in NICD degradation has been previously
reported [46–48]. However, to date, the NICD-FBXW7 interaction
has only been shown in overexpressed systems [36,38,46–48,63,64].
Thus, we examined the binding of NICD to FBXW7 using co-immu-
noprecipitation analysis at the endogenous level.
FBXW7 was immunoprecipitated from HEK293 cells treated with
DMSO or MLN4924 for 3 h, and extracts were probed with NICD
antibody. NICD directly binds to FBXW7 (Fig 2A). After MLN4924
treatment, an inhibitor of Cullin1 neddylation, the amount of NICD
bound to FBXW7 was significantly higher compared to control cells
and this was particularly evident with the higher molecular weight
isoform of NICD (Fig 2A and B), confirming again NICD-FBXW7
interaction is phosphorylation-dependent.
In order to determine whether the change in the NICD phospho-
rylation profile observed after treatment with the CDK inhibitors
reduced the NICD-FBXW7 interaction, we performed the same co-
immunoprecipitation assay after CDK inhibitor treatment. In order
to maximize the amount of NICD immunoprecipitated with FBXW7,
cells were treated with MLN4924 (to prevent NICD degradation) in
the presence or the absence of the CDK inhibitors. A significantly
reduced interaction between NICD and FBXW7 was observed after
treating HEK293 cells with Roscovitine or DRB for 3 h (Fig 2C and
Appendix Fig S2A). Statistical analyses, carried out on the density of
Western blot bands after immunoprecipitation, confirmed a signifi-
cant reduction in the interaction between NICD and FBXW7 follow-
ing either Roscovitine or DRB treatment (Fig 2D and Appendix Fig
S2B).
Taken together, these data demonstrate, for the first time, that
NICD interacts with FBXW7 at endogenous levels in HEK293 cells,
and this interaction is dependent on phosphorylation.
To further validate the involvement of FBXW7 in endogenous
NICD turnover, we conducted a siRNA-mediated depletion of
FBXW7 in HEK293 cells (Appendix Fig S2E). siRNA treatment effi-
ciently depleted FBXW7 protein levels and led to an increase in
levels of the FBXW7 target protein Cyclin E. FBXW7 depletion also
resulted in increased levels of NICD and, in particular, an accumula-
tion of the phosphorylated form of NICD (Appendix Fig S2E).
Serine 2513 is essential for the NICD-FBXW7 interaction
We utilized Mass Spectrometry as an unbiased approach to identify
which NICD residues are phosphorylated in HEK293 cells transiently
transfected with human NICD-GFP, followed by immunoprecipita-
tion of NICD-GFP. Gel slices were processed and submitted to MS
analysis. We identified 15 phospho-sites on exogenous hNICD, high-
lighted in green in Fig 3A. To investigate the relevance of those
phosphorylation sites in NICD turnover, we screened those located
within the PEST domain (such as S2527), and others based on the
FBXW7 phospho-degron motif (such as S2205, S2513, S2516,
S2538) which is known to be [RK] S/T P [RK] X S/T/E/D, where X
is any amino acid and RK is any amino acid except arginine (R) or
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lysine (K) [65]. CDKs are proline-directed kinases, so we also inves-
tigated the relevance of proline residues adjacent to the consensus
motif shared by most FBXW7 in NICD PEST domain.
Previous deletion studies have suggested some of these sites may
play a role in regulation of NICD turnover [36,63]. Thus, we gener-
ated eight NICD constructs each carrying either a serine to alanine,
threonine to valine or proline to leucine/arginine point mutations in
an identified site. Following transient transfection of HEK293
cells with wild-type or mutated peptides, we performed immunopre-
cipitation using GFP-conjugated beads, to evaluate peptide binding
efficiency with endogenous FBXW7. We found 7 of 8 of these
individual mutations (serine 2205, 2516, 2527 and 2538, threonine
2511 and proline 2512 and 2514) did not affect the NICD-FBXW7
interaction (Fig 3B, Appendix Fig S2F and G), at least in HEK293
cells. However, mutating serine 2513 to alanine, to render this
residue non-phosphorylatable, completely abolished the NICD-
FBXW7 interaction in this assay (Fig 3B). Cells transfected with the
double-mutant S2513A/S2516A also showed a dramatic loss of the
NICD-FBXW7 interaction. This did not reflect a reduction in the
level of immunoprecipitated GFP (Fig 3B).
Thus, our data suggest that only serine 2513, of those we have
tested, is the key NICD phosphorylation site required for interaction
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Figure 2. NICD and FBXW7 interact directly at endogenous levels.
A NICD interaction with FBXW7 at endogenous levels in HEK293 cells. 500 lg of HEK293 cell lysates treated with DMSO or MLN4924 was subjected to
immunoprecipitation using FBXW7 antibody, or IgG antibody as negative control, and precipitated material was analysed by Western blot using NICD antibody.
Western blot with FBXW7 antibody served as loading control for immunoprecipitation efficiency. 10% of cell lysate before immunoprecipitation was used as input
control and b-Actin served as loading control.
B Quantification of the density of Western blot bands in (A) performed by ImageJ software. Data are expressed as percentage changes compared to MLN4924. All data
represent the mean  SEM from three independent experiments. Student’s t-test was used to determine P values, with **P ≤ 0.01.
C Roscovitine treatment reduced the NICD-FBXW7 interaction. 500 lg of HEK293 cell lysates treated with MLN4924 or MLN4924 together with Roscovitine was
subjected to immunoprecipitation using FBXW7 antibody, or IgG antibody as negative control, and precipitated material was analysed by Western blot using NICD
antibody. Western blot with FBXW7 antibody served as loading control for immunoprecipitation efficiency. 10% of cell lysate before immunoprecipitation was used
as input control and b-actin served as loading control.
D Quantification of the density of Western blot bands in (C) performed by ImageJ software. Data are expressed as percentage changes compared to MLN4924-treated
samples. All data represent the mean  SEM from three independent experiments. Student’s t-test analysis was performed, with ***P ≤ 0.001.
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with FBXW7, and thus potentially crucial for NICD stability and
turnover.
Cyclin-dependent Kinase (CDK) 1 and 2 phosphorylate
NICD in vitro
Previous reports have proposed a number of potential kinases
which may be involved in NICD phosphorylation and turnover,
including CyclinC:CDK8 [36], CyclinC:CDKs [63], PKC [66], PIM
[67] and GSK3b [35,37] kinases. The MRC-PPU Kinase Profiling
Inhibitor Database (http://www.kinase-screen.mrc.ac.uk/kinase-
inhibitors) (University of Dundee) indicates that, at the concentra-
tions used in our assays, Roscovitine, in particular, is a potent inhi-
bitor of CDK2, but a very weak inhibitor of CK1, GSK3b and more
than 50 other kinases tested. In order to confirm results derived
from the Kinase Profiling Inhibitor Database, we performed a kinase
assay in collaboration with the MRC-PPU International Centre for
Kinase Profiling. We tested three NICD phospho-peptides against
the activity of a panel of different kinases including CDK1 and CDK2
(Table 1). Of seven kinases tested, 5 had no specific activity against
any of the peptides. In contrast, CDK1 and CDK2 elicited a very high
activity against Peptide 1, which contained serine residues 2513 and
2516, previously identified by mass spectrometry analysis to be
phosphorylated in NICD, and in particular 2513, we have shown to
be crucial for the NICD-FBXW7 interaction.
These results demonstrate that CDK1 and CDK2 phosphorylate
the C-terminal region of NICD in vitro. Therefore, we decided to
evaluate the contribution of these kinases to endogenous NICD turn-
over and FBXW7 interaction in the cell lines. CDK2 siRNA treatment
in HEK293 cells efficiently depleted CDK2 protein levels, with no
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Figure 3. Mass spectrometry analysis of phosphorylated residues in
hNICD.
A LC-MS-MS analysis of in-gel-digested HEK293 cells transfected with hNICD-
GFP and subjected to immunoprecipitation using GFP antibody, identified
multiple phosphorylation sites in NICD, highlighted in green.
B Phosphorylation of serine 2513, but not serine 2516, appears to be essential
for the NICD-FBXW7 interaction. hNICD-GFP phospho-mutant peptides
encoding non-phosphorylatable residues at S2513 and/or 2516 (serine to
alanine) were expressed in HEK293 cells. The exogenously expressed protein
was subsequently immunoprecipitated with anti-GFP antibody, and
precipitated material was analysed by Western blot using FBXW7 antibody.
Wild-type hNICD-GFP and GFP only vectors were included as positive and
negative controls, respectively. Western blot using GFP antibody served as
immunoprecipitation efficiency control. b-Actin has been used as loading
control for the input lanes.
Table 1. CDK1 and CDK2 exhibit specific activity against a NICD
phospho-peptide by in vitro kinase assay.
Specific
activity
(U/mg) Peptide 1 Peptide 2 Peptide 3 Control
Cdk1/CyclinA2 1035.43 35.21 7.86 1322
Cdk1/CyclinB 887.23 37.46 0.04 1566
Cdk2/CyclinA 79.7 0.5 0 117.7
Cdk5/p35 47 0.8 0.5 1729.5
Cdk7/MAT1/
CyclinH
0.1 0.2 0.1 21.6
Cdk9/CyclinT1 2.7 0.6 0.3 66.4
CK1a 0 0 0.1 19.1
GSKb 1 1 1.1 552.5
The figures in bold represent significant enzyme activity against the peptide
as compared to activity of the respective enzyme on their control substrate
in the last column.
Three NICD phospho-peptides were tested for the activity of seven different
kinases (CDK1, CDK2, CDK5, CDK7, CDK9, CK1a and GSKb). A known substrate
was used as control for each kinase. The specific activity of each kinase is
expressed in U/mg.
Peptide 1 contains serine residues 2513 and 2516
(HPFLTPSPESPDQWSSSSPH).
Peptide 2 includes serine 2538 (NVSDWSEGVSSPPTSMQSQIA).
Peptide 3 encompasses serine residue 2141 (GTPTLSPPLCSPNGYLGSLKP).
Peptide 1: S2513 and S2516 HPFLTPSPESPDQWSSSSPH.
Peptide 2: S2538 NVSDWSEGVSSPPTSMQSQIA.
Peptide 3: S2141 GTPTLSPPLCSPNGYLGSLKP.
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effect on levels of CDK1, CDK4 or CDK8. Under these conditions,
NICD levels were significantly increased compared to control scram-
bled siRNA-treated cells, indicative of reduced NICD turnover
(Fig 4A and B).
We repeated this assay and depleted CDK1 by a siRNA-mediated
approach in HEK293 cells. Under these conditions, we also observed
an increase in NICD protein levels compared to the control (Fig 4C),
and this increase was statistically significant (Fig 4D). Interestingly,
we also detected elevated levels of CDK2 and CDK8 following CDK1
depletion, suggesting a possible compensation effect was occurring
upon CDK1 knockdown. Nevertheless, this did not prevent the
effect of loss of CDK1 upon NICD turnover.
CDK8 has previously been proposed as a potential kinase
involved in NICD phosphorylation and turnover [36,63]. We moni-
tored NICD levels following efficient siRNA-mediated depletion of
CDK8 in HEK293 cells. This resulted in slightly elevated NICD levels
(Appendix Fig S3A and B). A marginal increase of CDK2 levels, but
not of CDK1 or CDK4, was also observed (Appendix Fig S3A), which
could suggest a compensation effect from CDK2 in the absence of
CDK8. These data suggest CDK8 may also phosphorylate NICD and
regulate its turnover as previously proposed, although in this assay
the effect of loss of CDK1 or CDK2 activity upon NICD levels is more
pronounced [36,63]. We detected no change in NICD levels follow-
ing efficient siRNA-mediated depletion of CDK4 in HEK293 cells
(Appendix Fig S3C).
Taken together, these data provide further validation of CDK1
and CDK2 involvement in NICD phosphorylation and turnover.
Pharmacological inhibition of CDK2 and CDK1 activity increases
levels of NICD in vitro
As a complementary approach to siRNA-mediated loss of function,
we selected two small molecule inhibitors that have a highly selec-
tive inhibitory activity against CDK2 kinase: Purvalanol B and
GSK650394A. The specificity of each of these kinase inhibitors has
been tested (at two different concentrations) by the International
Centre for Kinase profiling within the MRC Protein Phosphorylation
Unit at the University of Dundee. At 1 and 10 lM, Roscovitine
specifically inhibits more than 96% of CDK2 activity. Purvalanol B
inhibits more than 95% CDK2 activity, at 0.1 and 1 lM.
GSK650394A inhibits 99% of CDK2 activity at both 1 and 10 lM
(Fig 4E). CDK2 is by far the most sensitive target for all three inhibi-
tors (Fig 4E). HEK293 cells treated with Roscovitine, Purvalanol B
or GSK650394A (10, 0.1 and 10 lM, respectively) for 3 h exhibited
significantly increased NICD levels compared to control DMSO-
treated cells (Fig 4F and G). iPS cells cultured 3 h in the presence of
0.1 lM Purvalanol B also exhibited significantly elevated levels of
NICD as compared to DMSO-treated control cells, indicating this is a
conserved effect of CDK2 (Fig EV1E and F).
Given our observation that both CDK1 and CDK2 can phosphory-
late NICD peptides in vitro, we similarly treated HEK293 cells with a
CDK1-specific inhibitor, RO-3306 [68]. Following exposure to 10 lM
of RO-3306 for 3 h, HEK293 cells showed elevated NICD levels
compared to control DMSO-treated cells (Fig 4H and I). Moreover,
Phos-tag technology reveals RO-3306 and Purvalanol B have a
reduced number of phospho-bands as compared to MLN4924,
indicative of the fact these inhibitors act to reduce NICD phosphory-
lation and, as seen with MLN4924, the ladder of bands collapses to
a single band in the presence of k phosphatase (Appendix Fig S1B).
These data further support the hypothesis that both CDK1 and
CDK2 are likely to be involved in phosphorylation-mediated regula-
tion of NICD turnover.
Levels of NICD increase in HEK293T CDK2/ cells
As a complementary strategy to the siRNA-mediated or pharmaco-
logical inhibitor methods, we adopted a genetic approach to monitor
the effects of loss of CDK2 activity on NICD turnover. To that end,
we analysed levels of NICD by Western blot in HEK293T WT and
CDK2/ cells and observed a striking increase in NICD levels in
CDK2/ cells compared to the control (Fig EV2A and B). No
changes in CDK1 or CDK8 levels were detected in the CDK2/
cells. These data validate our previous findings, confirming the
implication of CDK2 in regulating NICD turnover. Given that we
◀ Figure 4. Depletion or pharmacological inhibition of CDK1 or CDK2 increased endogenous levels of NICD in HEK293 cells.A HEK293 cells were cultured for 48 h after transfection with plasmids encoding scrambled siRNA () or siRNA specific for CDK2 (+) followed by Western blot for NICD,
CDK2, CDK1, CDK4 and CDK8. b-Actin served as loading control.
B Quantification of the density of Western blot bands in (A) performed by ImageJ software. Data are expressed as fold changes compared to control (scrambled siRNA
transfected) cell lysate. All data represent the mean  SEM from three independent experiments. Student’s t-test analysis was performed, with **P ≤ 0.01.
C HEK293 cells were cultured for 48 h after transfection with plasmids encoding scrambled siRNA () or siRNA specific for CDK1 (+) followed by Western blot for NICD,
CDK1, CDK2, CDK4 and CDK8. b-Actin has been used as loading control.
D Quantification of the density of Western blot bands in (C) performed by ImageJ software. Data are expressed as fold changes compared to control (scrambled siRNA
transfected) cell lysate. All data represent the mean  SEM from three independent experiments. Student’s t-test analysis was performed, with *P ≤ 0.05.
E Analysis of the inhibitory activity of three highly selective CDK2 inhibitors against a panel of kinases—a selection of those tested is shown here. At both 1 and 10 lM,
Roscovitine is able to inhibit more than 95% of CDK2 activity, but is far less effective against other kinases. Purvalanol B (0.1 and 1 lM) inhibits more than 94% of
CDK2 activity. At both 1 and 10 lM, GSK650394A is able to inhibit more than 98% of CDK2 activity. Source: The Kinase Profiling Inhibitor Database (http://www.kina
se-screen.mrc.ac.uk/kinase-inhibitors).
F HEK293 cells were treated with three highly selective CDK2 inhibitors (10 lM of Roscovitine, 0.1 lM of Purvalanol B and 10 lM of GSK650394A) for 3 h. Endogenous
levels of NICD were detected by Western blot. b-Actin served as loading control.
G Quantification of the density of Western blot bands in (F) using ImageJ software. Data are expressed as fold changes compared to DMSO. All data represent the
mean  SEM from three independent experiments. One-way ANOVA analysis, followed by Dunnett’s test, was performed, with *P ≤ 0.05, **P ≤ 0.01, and ns = not
significant.
H HEK293 cells were treated with RO-3306, a specific CDK1 inhibitor, for 3 h at 10 lM. Levels of NICD, FBXW7, phospho-histone H3 and histone H3 were detected by
Western blot. b-Actin was used as loading control.
I Quantification of the density of Western blot bands in (H) using ImageJ software. Data are expressed as fold changes compared to DMSO. All data represent the
mean  SEM from three independent experiments. Student’s t-test analysis was performed, with *P ≤ 0.05.
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have implicated a role for CDK1 in phosphorylating NICD and regu-
lating NICD turnover (Fig 4), we asked whether the simultaneous
loss of both CDK1 and CDK2 would lead to an enhanced increase of
NICD levels. CDK1 siRNA treatment in WT or CDK2/ HEK293T
cells efficiently depleted CDK1 protein levels, with no effect on
levels of CDK2 or CDK8. Under these conditions, NICD levels were
significantly increased in CDK2/ cells compared to control scram-
bled siRNA-treated CDK2/ cells. This indicates a synergistic effect
following the simultaneous loss of both CDK1 and CDK2 that is
greater than that observed through loss of CDK2 alone. CDK8 levels
did not change under these conditions (Fig EV2C and D).
Taken together, these data suggest that in the total absence of
CDK2, NICD levels are elevated; furthermore, when CDK1 is also
depleted in CDK2/ cells, the increase in levels of NICD is more
pronounced. This confirms again that both CDK1 and CDK2 are key
kinases in phosphorylating the Notch intracellular domain.
NICD levels fluctuate over the cell cycle
It is well known that CDK1 and CDK2 share several substrates, with
a consequent functional redundancy [69]. Our data demonstrate
that these two kinases can phosphorylate NICD in vitro and in the
absence of either kinase NICD levels increase in HEK293 cells
suggesting they are not acting redundantly in this context. Indeed,
loss of both CDK1 and CDK2 activity leads to a synergistic effect
upon NICD levels in HEK293T cells. In order to further test this, we
analysed whether NICD levels fluctuate during the cell cycle where
the role of both CDK1 and CDK2 has been extensively reported in
regulating transition to distinct cell cycle phases [70].
To that end, we synchronized HEK293 cells by using a double
thymidine block assay. After releasing from the second thymidine
block, cells were collected at indicated time points and cell cycle
characterization was performed by fluorescence-activated cell sort-
ing (FACS) (Fig 5A).
Figure 5A shows the distribution though the cell cycle of HEK293
cells after synchronization at G1 (0 h), as previously reported [71].
Two and 4 h post-release, the majority of cells were in S phase. At
6 h post-release, the majority of cells were in G2 phase, while 8 h
after release, the majority of cells were in late G2/early M phase. At
10 h post-release, the majority of cells had exited mitotic phase and
already entered G1. After 12 h from release, cells were in late G1 of
the new cell cycle (Fig 5A). The graph in Fig EV3A represents the
cell cycle distribution of HEK293 cells at distinct time points post
double thymidine block and release from three independent experi-
ments analysed by FACS.
Western blotting analysis of synchronized HEK293 cell extracts
showed the expression of several cell cycle regulatory proteins at
the same distinct time points reflecting distinct cell cycle phases as
described above (Fig 5B). Interestingly, we found that NICD levels
fluctuated in a striking manner during the cell cycle, whereas we
saw no change to levels of FBXW7. We observed a dramatic
decrease of NICD levels at 2 and 4 h corresponding to CDK2-depen-
dent G1/S phase, and again 8 h after double thymidine block release
corresponding to the CDK1-dependent G2/M phase transition. These
data suggest that NICD levels fluctuate during the cell cycle in a
CDK1- and CDK2-dependent manner (Fig EV4). To further explore
this, we repeated this Western blot analysis on synchronized
HEK293T CDK2 knockout cell extracts. We found a reduced
effect upon fluctuations in NICD levels as compared to control
cells (Figs 5B and EV3D). Nevertheless, some fluctuation was
observed which may be attributable to functional compensation
provided by CDK1 and associated Cyclin activity in the absence of
CDK2 [72,73].
In addition, we analysed the cell cycle distribution by flow
cytometry in HEK293 cells after CDK2-siRNA-mediated depletion
which we have shown leads to a significant increase in NICD levels
(Fig 4A) and we observed a slight but nevertheless statistically
significant accumulation of cells in G1 phase compared to the
control, as expected for cells deprived of CDK2 activity and there-
fore unable to pass the G1/S checkpoint (Figs 5C and EV3B). These
data suggest that the drop in NICD levels occurring in G1/S phase is
due to CDK2 phosphorylation of NICD. Similarly, cell cycle distribu-
tion, analysed by flow cytometry in HEK293 cells, after CDK1-
siRNA-mediated depletion reveals a marginal but nevertheless
significant accumulation of cells in G2 phase compared to the
control, as expected for cells deprived of CDK1 activity and there-
fore unable to pass the G2/M checkpoint (Figs 5D and EV3C).
We next investigated whether this fluctuation of NICD levels
during different phases of the cell cycle was a conserved phenom-
enon by quantifying NICD distribution through the cell cycle in a
different cell line.
iPS cells were analysed by immunofluorescence using DAPI to
mark nuclei and to also distinguish cells in M Phase. The Click-iT
EdU assay was used to distinguish cells in S phase, as well as anti-
bodies to NICD and Cyclin A. NICD intensity was measured in order
to quantify NICD signal throughout the different stages of the cell
cycle. We observed NICD levels were increased significantly during
G1 and G2 (Fig 6A and B), which complements our observations in
HEK293 cells (Fig 5B). These data demonstrate that fluctuations of
NICD levels occur during the cell cycle in a manner that reflects
fluctuations in CDK activity (Fig EV4) and this is conserved across
different cell types.
Pharmacological inhibition of CDK2 increases NICD levels and
delays the pace of the segmentation clock in the PSM
In order to address whether CDK2 phosphorylation of NICD is
involved in driving the NICD-FBXW7 interaction, we performed a
co-immunoprecipitation assay with FBXW7 antibody and analysed
NICD by Western blot after CDK2 inhibitor treatment. As above, in
order to maximize the amount of NICD immunoprecipitated
HEK293 cells were treated with MLN4924 (to prevent NICD degra-
dation) +/ Purvalanol B (0.1 lM). A significantly reduced interac-
tion between NICD and FBXW7 was observed after treating HEK293
cells with Purvalanol B for 3 h. This did not reflect a reduction in
the level of immunoprecipitated FBXW7 (Fig 7A). Statistical analy-
sis on the density of Western blot bands after immunoprecipitation
confirmed an extremely significant reduction in the NICD-FBXW7
interaction following Purvalanol B treatment (Fig 7B). A similar but
albeit less pronounced effect was seen with GSK650394A
(Appendix Fig S2C and D).
In order to address the potential in vivo role of CDK2-mediated
NICD phosphorylation during somitogenesis, we cultured E10.5
mouse PSM explants for 4 h in the presence of 1 lM of Purvalanol
B. Initially, we analysed NICD levels by Western blot and just as in
the in vitro context, CDK2 inhibition resulted in increased NICD
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Figure 5. NICD levels fluctuate during the cell cycle.
A Cell cycle profile for HEK293 cells released from synchronization after double thymidine block. Cells were released and harvested at the indicated time points
(AS = asynchronous). Analysis of cell cycle arrest and release was performed using propidium iodide (PI) staining and flow cytometry. A representative experiment
of three performed is shown.
B Expression of the indicated proteins in HEK293 cells was examined by Western blotting, and b-actin was used as loading control. This summary is a representation
of three independent experiments.
C, D Graph of flow cytometry data shows the percentage of cells in given cell-cycle phases 48 h after transfection with plasmids encoding scrambled siRNA or siRNA
specific for CDK2 (C) or CDK1 (D). Graphs represent the mean of three independent experiments. All data represent the mean  SEM from three independent
experiments. Student’s t-test analysis was performed, with *P ≤ 0.05 and **P ≤ 0.01 (ns = not significant).
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levels as compared to control embryos (Fig 7C and Appendix Fig
S3D). This provides the first in vivo evidence CDK2 is likely to be
involved in NICD turnover.
Previous reports have suggested perturbations to NICD turnover
leading to increased NICD levels/stability are closely linked to an
increase in the period of segmentation clock oscillations in the PSM
[21]. To further explore whether clock gene oscillations were delayed
following CDK2 inhibition, we used the half embryo assay, where the
PSM from one half of an E10.5 mouse embryo is cultured in control
media, while the contralateral half from the same embryo is cultured
in the presence of 1 lM of Purvalanol B for 4 h. In 55.5% of cases
examined (n = 10/18, Table 2A), exposure of PSM explants to Purva-
lanol B caused a delay in the pace of oscillatory mLfng expression
across the PSM as compared to the control explant (Fig 7E and
Appendix Fig S3Fa-b). Also, in some cases the treated explant (“+”)
developed one somite less compared to the control (Fig 7E).
Additionally, we cultured E10.5 mouse PSM explants in the pres-
ence or absence of the CDK1 inhibitor, RO-3306, for 4 h at 10 lM.
Analysis of NICD levels by Western blot revealed that inhibition of
CDK1 leads to elevated levels of NICD compared to control embryos
(Fig 7D and Appendix Fig S3E). Furthermore, 60% of E10.5 mouse
half embryo explants (n = 6/10, Table 2B) exposed to RO-3306
treatment for 4 h showed delayed clock oscillations of mLfng as
compared to DMSO-treated contralateral half embryo explants
(Fig 7F and Appendix Fig S3Fc-d).
Finally, considering the assumption that a longer clock period
will result in fewer bigger somites in a given time, we performed an
analysis similar to that previously reported in Wiedermann et al
[21] to examine the effect upon somite size following treatment with
1 lM of Purvalanol B or 10 lM of RO-3306 for 7.5 h. By measuring
the absolute somite size, we observed that drug-treated embryos
display a trend with the last formed somite being larger compared
to DMSO control embryos.
In addition, we computed the fold change of successive somite
sizes within an embryo (log2 of ratio of somite sizes). Using a
nomenclature whereby +1 refers to the most recently formed somite,
this corresponds on average to four somites after the drug was
added. Thus, by +2 we mean the penultimate somite, which corre-
sponds on average to three somites after the drug was added. Once
more, we could appreciate a clear trend for both Purvalanol B and
RO-3306-treated embryos showing an increase in the last formed
somite, which was not present in control DMSO embryos (Fig 7G
and H). These results are consistent with the current understanding
that the position of the somite boundaries is already specified for
the first few somites that will form from the anterior region of the
PSM [74], and thus for those that form just after the time when the
drug was added. Our data thus suggest that somite boundary posi-
tion has been specified at +1, +2, +3 but not at +4.
Taken together, these data not only support our in vitro findings,
but also importantly provide, for the first time, the in vivo evidence
that CDK1 and CDK2 are involved in NICD stability and turnover
and that this molecular regulation of NICD turnover is extricably
linked to the segmentation clock.
Mathematical model links NICD regulation and cell cycle
To understand how our findings on the molecular details of NICD
regulation in individual cells give rise to tissue-scale delay of the
segmentation clock, we first developed a mathematical model of
NICD production and degradation in HEK293 cells. The variables in
the model define the position of a cell in the cell cycle, the amount
of NICD and the amount of phosphorylated NICD (pNICD) at time t.
The model enables us to connect assumptions about molecular
processes in individual cells with experiments performed on a large
population of cells (see Appendix Fig S4).
By averaging cellular descriptions of NICD and the cell cycle over
a given cell population, we derive equations describing the average
levels of total NICD (i.e. as measured in a Western blot experiment,
see Materials and Methods). Upon release from double thymidine
block, cells are synchronized in the cell cycle and there are rela-
tively high levels of CDK activity at different times post-release. As
pNICD degrades faster, high levels of CDK results in lower levels of
NICD (see Appendix Fig S4 and Figs 4A–D and F–I, and 5B,
Appendix Fig S3D and E). We find the model qualitatively fits the
experimental observations if NICD is phosphorylated in two sepa-
rate time windows post-release. We propose that these windows
correspond to activity of CDK2 (G1/S phase) and CDK1 (M phase)
(Appendix Fig S4A and B). The model can reproduce Western blot
results from DMSO and MLN4924 experiments (Appendix Fig S4C).
Notably, the simulated Purvalanol B/Roscovitine treatment experi-
ment presented in Appendix Fig S4C is a prediction that is validated
by the experimental data (Figs 1B and D, and 4G).
To explore how CDK inhibition results in delay of the segmenta-
tion clock, we introduce an additional variable representing phase
of the somitogenesis clock and assume that the caudal PSM behaves
like a population of phase-coupled oscillators. Given sufficiently
strong coupling, a population of such oscillators yields synchronous
oscillations with a period that is an average of the individual oscilla-
tor periods (Appendix Fig S4E and F). Upon CDK inhibition, the
relative number of faster oscillators is reduced; hence, the average
period decreases (Appendix Fig S4E). Thus, the cell cycle somitoge-
nesis coupled model provides a description of how CDK-mediated
phosphorylation of NICD can result in the observed phenotype in
PSM tissue (Fig 7).
Discussion
In this study, we report for the first time that cell cycle-dependent
CDK1 and CDK2 activity is involved in NICD turnover, linking NICD
turnover with the cell cycle which has broad implications across all
developmental and disease contexts where Notch plays a role.
We demonstrate that inhibitors (Roscovitine, DRB and XAV939),
previously shown to prolong NICD half-life and delay the segmenta-
tion clock pace in mouse and chick PSM in vivo [21], also increase
endogenous levels of human NICD when a range of primary human
cell lines were treated for 3 h. This highlights the conserved effect of
these inhibitors on regulating NICD stability, which is perhaps not
surprising given the high degree of sequence similarity between
mouse, human and chicken NICD. While it is true we cannot formally
exclude the possibility that the inhibitors may also affect full length
Notch, it is nevertheless clear they have an effect on NICD stability
since in the presence of LY411575, which inhibits Notch processing,
we see an increase in levels of the processed form.
A number of reports have highlighted the fact that the SCFFBXW7
E3 ligase plays an important role in NICD degradation
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Figure 6. NICD levels peak in G1 and G2 phases of the cell cycle for iPS cells.
A iPS cells in G2 express high levels of Cyclin A and do not incorporate EdU (marked in red within the NICD panel). EdU incorporation occurs during S phase (marked by
yellow in the NICD panel). Cells with low Cyclin A intensity and no EdU incorporation are either in G1 or M phase. M phase cells are distinguishable by their
chromatin condensation, observable in the DAPI panel (dividing cells are indicated with white in the NICD panel). G1 cells do not have any of the features described
above (blue in NICD panel). Scale bars are 20 lm.
B G1 and G2 phase cells have significantly higher NICD protein levels than S and M stage cells (P ≤ 0.001). All groups were compared against each other with a one-
way ANOVA analysis, followed by Tukey’s test. M phase cells have the lowest NICD. Each point in the box-plot represents the normalized intensity of a single cell.
Data from three different experiments (n = 3) were randomized collated and plotted.
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[36,38,46–48,64]. To date, the interaction between NICD and
FBXW7 by co-immunoprecipitation has only been shown using
overexpressed proteins, due to the fact this interaction is very tran-
sient and leads to efficient degradation of NICD [36,38,47,48,64].
We demonstrate for the first time that NICD and FBXW7 can interact
at endogenous levels in HEK293 cells. Moreover, this allowed us to
demonstrate that, when phosphorylation is disrupted by small mole-
cule CDK inhibitors (Roscovitine, Purvalanol B or DRB), the NICD-
FBXW7 interaction is reduced. It is important to note that none of
these inhibitors abolished the NICD-FBXW7 interaction, which
suggests again that they are each inhibiting only some of the kinase
activity involved in NICD phosphorylation and subsequent recruit-
ment of FBXW7. This aligns with the observation that in the
chicken/mouse PSM both of these inhibitors increase NICD stability
and the period of the segmentation clock but that NICD turnover
still occurs in this tissue and thus is dependent on a number of dif-
ferent kinases/phosphorylation events differentially targeted by
these two inhibitors [21].
By mass spectrometry analysis, we identified 15 phospho-sites
within human exogenous NICD in HEK293 cells, some of which
have been previously identified and reported to be involved with
NICD turnover [36,63]. Among those phospho-sites identified, we
found that Serine 2513, when mutated to alanine, thereby rendering
the site non-phosphorylatable, was essential for the interaction
between NICD and FBXW7. Point mutations in a number of other
phosphorylated residues showed these are non-essential for this
NICD-FBXW7 interaction, including two residues that have previ-
ously been reported to potentially be required for the interaction;
S2484 and S2506 (S2516 and S2538 in our annotation) [36,64].
However, Fryer and colleagues used exogenous proteins and
mutated all three sites simultaneously, so the individual contribu-
tion/requirement of each residue was not addressed in that study.
O’Neil and colleagues have also reported, using exogenous proteins,
that phosphorylation of the threonine residue at T2487 in mouse
NICD (T2511 in our annotation) is key to driving the NICD-FBXW7
interaction and subsequent ubiquitination of NICD [38]. We did not
observe phosphorylation at this residue in human NICD. However,
it would be interesting to repeat the mass spectrometry analysis
using different enzyme digestions to determine whether this reveals
additional phosphorylated sites that play a role in this interaction.
We have identified CDK1 and CDK2 as two kinases that can
phosphorylate NICD in the PEST region that harbours residue serine
2513, which we have demonstrated to be crucial for the interaction
between NICD and FBXW7. Through three loss-of-function
approaches, namely siRNA, generation of CDK2 knockout cell line
and a pharmacological approach, we further demonstrated that
inhibiting phosphorylation by CDK1 or CDK2 renders NICD more
stable.
CDK1 and CDK2 activity, and thus phosphorylation of their
substrates, changes in a cell cycle-dependent manner [75]. Strik-
ingly, we find that NICD levels vary in HEK293 cells and iPS cells in
a cell cycle-dependent way such that we observe lowest levels of
NICD in phases of the cell cycle where CDK1/Cyclin B1 and CDK2/
Cyclin E levels are highest and therefore when these complexes are
reported to be most active [76]. This finding suggests that NICD
activity, signal duration and signal strength are likely to vary in a
cell cycle-dependent manner, potentially leading to differential tran-
scriptional outputs in different phases of the cell cycle.
Given our findings, it is striking that CDK2 homozygous null
mice are viable [72]. However, it has been reported that CDK1 and
CDK2 share more than 50% of their targets [77] which is likely to
allow for some redundancy in this knockout line, as CDK1 can
compensate for loss of CDK2 by forming active complexes with A-,
B-, E- and D-type Cyclins. Indeed, we find inhibiting both CDK1 and
CDK2 activity simultaneously in HEK293T cells led to a synergistic
effect on NICD levels. The CDK1-null homozygous mice however
are embryonic lethal, and a CDK2 knock-in to the CDK1 locus is
unable to rescue this phenotype [78,79]. It would be interesting to
examine the role of the CDK1 conditional mutant in the context of
Notch signalling and somitogenesis [80]. Interestingly, Cyclin C-null
mice, which are embryonic lethal at 10.5, show dramatically
reduced NICD1 phosphorylation in vivo and elevated NICD1 levels.
The authors show that Cyclin C can complex with CDK3, CDK19,
CDK8, CDK1 and CDK2 to phosphorylate NICD1 and promote
◀ Figure 7. Purvalanol B treatment reduces the NICD-FBXW7 interaction and CDK1 or CDK1 inhibition delays the pace of the segmentation clock.A Purvalanol B treatment reduced the NICD-FBXW7 interaction. 200 lg of HEK293 cell lysates treated with MLN4924 or MLN4924 in combination with 0.1 lM of
Purvalanol B was subjected to immunoprecipitation using FBXW7 antibody, or IgG antibody as negative control, and precipitated material was analysed by Western
blot using NICD antibody. Western blot with FBXW7 antibody served as loading control for immunoprecipitation efficiency. 10% of cell lysate before
immunoprecipitation was used as input control and b-actin has been used as loading control.
B Quantification of the density of Western blot bands in (A) performed by ImageJ software. Data are expressed as percentage changes compared to MLN4924-treated
samples. All data represent the mean  SEM from three independent experiments. Student’s t-test analysis was performed, with ***P ≤ 0.001.
C E10.5 mouse tails were bisected down the midline. One half (+) was cultured for 4 h in the presence of Purvalanol B (1 lM). The contralateral half () was cultured
for 4 h in the presence of DMSO. Control or treated explants were pooled, and NICD levels were detected by Western blot. b-Actin was used as loading control.
D E10.5 mouse tails were bisected down the midline. One half (+) was cultured for 4 h in the presence of RO-3306 (10 lM). The contralateral half () was cultured for
4 h in the presence of DMSO. Control or treated explants were pooled, and NICD levels were detected by Western blot. b-Actin has been used as loading control.
E Bisected E10.5 mouse PSM explants were cultured in the absence () or presence (+) of 1 lM of Purvalanol B for 4 h and then analysed by in situ hybridization for
mLfng mRNA expression. Purvalanol B-treated explant has one less somite than the control explant, and the treated explant is in the same late phase 1 of the
oscillation cycle of dynamic mLfng mRNA expression indicating it is a whole cycle delayed compared to the “” explant. n = 18. Scale bar is 100 lm.
F Bisected E10.5 mouse PSM explants were cultured in the absence () or presence (+) of 10 lM of RO-3306 for 4 h and then analysed by in situ hybridization for
mLfng mRNA expression. RO-3306-treated explant is two phases behind in the oscillation cycle of dynamic mLfng mRNA expression indicating there is a delay in the
oscillation compared to the “-” explant. n = 10. Scale bar is 100 lm.
G The mean log2 fold change in successive somite length at position +1 (last formed somite) is plotted for different treatment conditions. Error bars denote standard
error of the mean. Paired t-test analysis was performed at 5% significance level, with P = 0.0437 for RO-3006 and P = 0.0524 for PurB, compared to DMSO. n = 14.
H The mean log2 fold change in successive somite length at position +2 (penultimate formed somite) is plotted for different treatment conditions. Error bars denote
standard error of the mean. Paired t-test analysis was performed at 5% significance level, with P = 0.6409 for RO-3006 and P = 0.4065 for PurB, compared to DMSO.
n = 14.
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NICD1 degradation [63]. Thus, it would be very interesting to exam-
ine a PSM conditional Cyclin C loss of function to determine
whether this Cyclin is involved in regulating NICD turnover in this
tissue. It is noteworthy Cyclin C levels did not appear to vary in a
cell cycle-dependent manner in HEK293 cells, although it is possible
the activity of Cyclin C/CDK complexes varies in a cell cycle-depen-
dent manner through post-translational modifications rather than
protein levels per se.
The finding that CDK1 or CDK2 inhibition leads to increased
levels of NICD in E10.5 mouse embryo PSM lysates and to a delay
in clock gene oscillations and somite formation provides the first
in vivo mechanistic evidence that both CDK1 and CDK2 are involved
in NICD turnover.
It is noteworthy that inhibition of CDK2 activity with a highly
selective inhibitor reduces the NICD-FBXW7 interaction in HEK293
cells but does not block it completely. This suggests that some NICD
turnover persists under these conditions, possibly through redun-
dancy between CDK1 and CDK2 and/or through CDK8-mediated
phosphorylation, the subsequent recruitment of E3 ligases and
degradation of NICD. Moreover, a report by Chiang et al has also
Table 2. Purvalanol B and RO-3306 small molecule inhibitors delays the pace of the segmentation clock.
Sample no.
Before treatment DMSO PurB
No. of somites No. of somites Phase No. of somites Phase
(A)
1 6.5 8 Ph2 7 Ph3
2 4.5 6.5 Late Ph1 6.5 Ph3
3 4.5 7.5 Ph3 6.5 Ph2
4 6 8 Early Ph2 8 Early Ph2
5 8.5 11 Ph3 11 Ph3
6 6 9 Ph3 9 Ph3
7 7 9 Early Ph2 9 Early Ph2
8 6 7 Ph3 7 Ph3
9 6 7 Late Ph3 6 Late Ph2/early Ph3
10 6 7 Ph2 (new cycle) 7 Ph3 (previous cycle)
11 6 7 Ph3 7 Ph3
12 4.5 5.5 Ph3 5.5 Ph3
13 4 5 Ph3 5 Ph3
14 6 7 Ph3 6 Ph2
15 6 7 Ph3 6 Ph3
16 5.5 8 Late Ph1 7 Late Ph1
17 7 9 Ph2 8 Ph2
18 5 6 Ph2 5 Ph2
Sample no.
Before treatment DMSO RO-3306
No. of somites No. of somites Phase No. of somites Phase
(B)
1 6 8 Ph3 7 Ph2
2 3.5 5 Late Ph3 4 Late Ph2/early Ph3
3 5.5 7 Ph2 (new cycle) 7 Ph3
4 5 6 Ph3 6 Ph2
5 3.5 6 Ph3 4 Ph2
6 4 6 Ph3 5 Ph3
7 5 7 Ph3 7 Ph3
8 4 6 Ph3 6 Ph3
9 4 6 Early Ph3 5 Ph2
10 4.5 6 Ph3 6 Ph3
Summary table of number of somites and clock delays before and after treatment with Purvalanol B (A) and RO-3306 (B) inhibitors, compared to DMSO, in E10.5
mouse explants.
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identified a region downstream of the PEST sequence, termed S4,
that is involved in NICD degradation, but that is independent of
FBXW7 activity [81]. These data indicate there are several mecha-
nisms regulating NICD turnover, which are partially redundant.
We also developed a mathematical model that coupled cell cycle
dynamics to NICD degradation. Using HEK293 cells, model parame-
ters were identified that recapitulated the distributions of cells in the
different cell cycle phases. To recover qualitative features of NICD
thymidine release experiments, NICD phosphorylation was required
at distinct stages in the cell cycle. After using MLN4924 and control
experiments to estimate NICD phosphorylation rate, the model qual-
itatively predicts the effect of Roscovitine/PurB treatment on total
NICD levels. To address the likely effect of CDK2 inhibition in the
PSM, the model was extended to account for position of a cell in the
segmentation clock cycle. Following Wiedermann et al [21], it was
assumed that levels of NICD are anti-correlated with clock somitoge-
nesis frequency. Hence, the posterior PSM is represented by a popu-
lation of phase-coupled oscillators whose frequency is cell cycle
dependent. Simulating CDK2 inhibition removes a pool of faster
oscillators thus reducing the tissue period.
Notch plays a key role as a gatekeeper protecting progenitor
and/or stem cells in multiple developmental contexts, in part
through preventing differentiation and in part through regulating
components of the cell cycle [82–84]. Our novel finding of a recipro-
cal auto-regulatory role between the cell cycle regulated CDKs,
CDK1 and CDK2, and NICD turnover has potentially great relevance
to the developmental biology community and may provide addi-
tional insight into disease/cancer contexts where this autoregulation
may have gone awry.
Materials and Methods
All plasmids and reagents indicated as such in the text are available
from MRC-PPU Reagents and Services (https://mrcppureagents.
dundee.ac.uk/).
Cell culture
HEK293 (human embryo kidney cells) and IMR90 (Human Caucasian
fetal lung fibroblast) cells were obtained from the American Type
Culture Collection (ATCC). Cells were routinely cultured and main-
tained in DMEM High glucose (Gibco) supplemented with 10% Fetal
Bovine Serum (FBS; LabTech), 1% Penicillin/Streptomycin (Gibco),
1% Sodium Pyruvate (Gibco) and 2 mM L-Glutamine (Gibco).
mESCs (mouse embryonic stem cells) were cultured on gelatin-
coated plates in media containing LIF, 10% fetal calf serum (Gibco)
and 5% knockout serum replacement (Invitrogen).
ChiPS4 human-induced pluripotent stem (iPS) cells (derived
from new born human dermal fibroblasts) were purchased from
Cellartis AB and maintained using DEF-CS (Cellartis AB) according
to the manufacturer’s recommendations. For experiments, cells
were seeded as single cells on GeltrexTM-coated dishes (10 lg/cm2)
in DEF medium supplemented with 10 lM of Rho-kinase inhibitor
Y27632 (Tocris) at a density of 1 × 54 cells/cm2 and allowed to
attach overnight. The medium was then replaced with fresh DEF
medium (Y27632), and after a further 24 h, cells were treated with
inhibitors.
The CDK2 homozygous mutant cell line was generated in
HEK293T cells (ATCC CRL-3216, Manassas, VA). The Integrated
DNA Technologies (IDT, Coralville, IA) Alt-R CRISPR-Cas9 ribonu-
cleoprotein system was used.
Briefly, a custom crRNA to the human CDK2 locus was designed
using the optimized primer design at crispr.mit.edu (CAGAAACAA
GUUGACGGGAG-GUUUUAGAGCUAUGCU). Cas9:crRNA:tracrRNA,
ATTOTM-550 ribonucleoprotein complexes were transfected into
293T cells with Lipofectamine RNAiMAX transfection reagent
(#13778100, Invitrogen, Grand Island, NY) following the recom-
mended protocol from IDT for cationic lipid delivery into mamma-
lian cells. The fluorescent tag labelled tracrRNA, ATTOTM-550, was
used to sort for transfected cells 24 h post-transfection.
ATTOTM550-positive cells were single cell sorted into 96-well plates
and expanded. Clones were screened for deletions by nested PCR
(Forward primer: CAAATTGACAAGAGCGAGAGG, Internal primer:
AAGTTGACGGGAGAGGTGGT, Reverse primer: AGTCAGGGTGTG
GTTTTTGG) and confirmed by Sanger sequencing.
All cells were grown at 37°C in 5% CO2. Cells were trypsinized
and split into new plates at subconfluency.
Transfections
Overexpression transfections
HEK293 cells were seeded 24 h prior to transfection and then tran-
siently transfected following the GeneJuice Transfection Reagent
protocol provided by Merck Millipore. Depending on plate size,
2–9 lg of plasmid was used. Cells were harvested 24 h after
transfection.
siRNA transfections
Small interfering RNA oligonucleotides were purchased from MWG/
Eurofins and used in a stock concentration of 20 lM. siRNAs were
transfected using calcium phosphate transfection method [85].
siRNA oligonucleotides were diluted in a solution containing
distilled sterile H2O and 2M CaCl2.
The mixture was then added dropwise to a round-bottom 15-ml
tube containing 2× HBS (0.137M NaCl, 0.75M Na2HPO4, 20 mM
HEPES pH 7.0). The content was then added to cells and incubated
overnight at 37°C.
Media was changed after 24 h, and cells were harvested after
48 h of transfection.
Oligonucleotide sequences for siRNA knockdown siRNA (50?30)
Control: AACAGUCGCGUUUGCGACUGG; CDK1: AAGGGGUUCC
UAGUACUGCAA; CDK2: CCUCAGAAUCUGCUUAUUA; CDK4: AA
GCCGACCAGUUGGGCAAAA; FBXW7: ACAGGACAGUGUUUACAAA.
Commercial CDK8 siRNA (Cell Signalling, #6438) has been used.
Plasmids and mutagenesis
hNICD-GFP vector was generated and obtained from MRC-PPU
reagents, University of Dundee. All NOTCH1 mutants were gener-
ated and obtained from MRC-PPU reagents, University of Dundee.
Briefly, the fragment NOTCH1 1,754–2,555 (end) was synthe-
sized by GeneArt with flanking BamHI and NotI restriction sites to
facilitate cloning, and the sequence was codon-optimized for
16 of 22 EMBO reports e46436 | 2019 ª 2019 The Authors
EMBO reports Francesca Anna Carrieri et al
Published online: April 17, 2019 
mammalian expression. This was then digested and ligated into
expression vector pCMV5D GFP to make the wild-type clone
pCMV5D GFP NOTCH1 1,754-end.
Site-directed mutagenesis was carried out using the QuikChange
Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) but
substituting the Taq with KOD Hot Start DNA polymerase
(Novagen). All mutations were confirmed by sequencing.
S2205A change was introduced using primers
Forward: 50-CCCGTGGATAGCCTGGAAGCGCCTCACGGCTACCTGAGC
Reverse: 50-GCTCAGGTAGCCGTGAGGCGCTTCCAGGCTATCCACGGG
S2513A change was introduced using primers
Forward: 50-CCCATTTCTGACCCCTGCACCCGAGAGCCCCGATC
Reverse: 50-ATCGGGGCTCTCGGGTGCAGGGGTCAGAAATGGG
S2516A change was introduced using primers
Forward: 50-CTGACCCCTAGCCCCGAGGCGCCCGATCAGTGGTCTAGC
Reverse: 50-GCTAGACCACTGATCGGGCGCCTCGGGGCTAGGGGTCAG
S2513A and S2516A double mutant was generated with primers
Forward: 50-CACCCCTTCCTCACCCCGGCCCCTGAGGCCCCTGAC
CAGTGGTCCA
Reverse: 50-TGGACCACTGGTCAGGGGCCTCAGGGGCCGGGGTGAG
GAAGGGGTG
S2527A change was introduced using primers
Forward: 50-TCTAGCAGCAGCCCCCACGCGAACGTGTCCGATTGGAGC
Reverse: 50-GCTCCAATCGGACACGTTCGCGTGGGGGCTGCTGCTAGA
S2538A change was introduced using primers
Forward: 50-TGGAGCGAAGGCGTGTCCGCCCCCCCAACCAGCATGCAG
Reverse: 50-CTGCATGCTGGTTGGGGGGGCGGACACGCCTTCGCTCCA
T2511V mutant was generated with primers
Forward: 50-CCCGAGCACCCATTTCTGGTCCCTAGCCCCGAGAGCCCC
Reverse: 50-GGGGCTCTCGGGGCTAGGGACCAGAAATGGGTGCTCGGG
P2512L change was introduced using primers
Forward: 50-GAGCACCCATTTCTGACCCTTAGCCCCGAGAGCCCCGAT
Reverse: 50-ATCGGGGCTCTCGGGGCTAAGGGTCAGAAATGGGTGCTC
P2514R change was introduced using primers
Forward: 50-CCATTTCTGACCCCTAGCCGCGAGAGCCCCGATCAGTGG
Reverse: 50-CCACTGATCGGGGCTCTCGCGGCTAGGGGTCAGAAATGG
Treatments
Cells were treated for 3 h with different drugs: 150 nM of LY411575
(generated in house, University of Dundee) [9], 1 lM of MLN4924
(MRC-PPU reagents, University of Dundee), 10 lM of 5,6-Dichloro-
1-beta-D-ribofuranosylbenzimidazole (DRB) (Sigma), 10 lM of
Roscovitine (Calbiochem), 10 lM of XAV939 (Tocris Bioscience),
0.1 lM of Purvalanol B (MRC-PPU reagents, University of Dundee),
10 lM of GSK650394A (MRC-PPU reagents, University of Dundee),
10 lM of RO-3306 (Sigma) and DMSO (Sigma) as control.
Lysates were treated with k-phosphatase (New England BioLabs)
following the manufacturer’s instructions.
iPS cells were incubated with nucleotide analogue EdU (Invitro-
gen) with a final concentration of at 40 lM.
Protein extraction
Cells were lysed on ice for 15 min by adding the appropriate volume
of lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 10 mM NaF, 1 mM Na3VO4, 0.1% b-mercap-
toEtOH, 1 tablet of protease inhibitor cocktail, Thermo Scientific).
Cells were harvested by scraping, and the lysate was clarified by
centrifugation for 15 min at 14,000 g at 4°C. The supernatants were
collected and stored at 80°C.
Bradford reagent (Bio-Rad) has been used as the colorimetric
assay for protein measurements.
Western blot
20 to 50 lg of protein was diluted 1:1 with 2× loading buffer
(100 mM Tris–HCL pH 6.8, 20% glycerol, 4% SDS, 200 mM DTT
and Bromophenol Blue), and proteins were denatured for 5 min at
95°C. Samples were resolved on a SDS–PAGE following standard
procedures.
Gels were transferred onto Nitrocellulose membrane (GE Health-
care) for 1.5 h at 400 mA. The membrane was then blocked with 5%
Milk in TBS-tween buffer (20 mM Tris pH 7.6, 150 mM NaCl, 0.1%
Tween) for 20 min. Membranes were incubated 30 min/1 h or O/N
at 4°C in primary antibodies [Cleaved Notch1 (1:1,000, Cell Signal-
ling #4147); b-Actin (1:10,000, Proteintech #66009-1-Ig); Fbxw7
(1:1,000; Abcam #171961); GFP (1:1,000, Cell Signalling #2956);
Cdk1 (1:1,000, Cell Signalling #9116); Cdk2 (1:1,000, Cell Signalling
#2546); Cdk4 (1:1,000, Santa Cruz #260); Cdk6 (1:1,000, Santa Cruz
#177); Cdk8 (1:1,000, Bethyl #A302-501A-T); Cyclin A2 (1:1,000,
Cell Signalling #4656); Cyclin B1 (1:1,000, Cell Signalling #4138);
Cyclin C (1:1,000, Bethyl #A301-989A-M); Cyclin D1 (1:5,000,
Abcam #137875); Cyclin E1 (1:1,000, Cell Signalling #4129); Total
histone H3 (1:1,000, Cell Signalling #9715); Phospho-histone H3
(1:1,000, Cell Signalling #3377)].
The membranes were then washed with TBS-Tween and incu-
bated with the appropriate secondary HRP antibody (Cell Signalling,
#7074, #7076). After washing, membranes were developed using
ECL solution (Pierce).
Western blot quantification
For band intensity quantification method, exposed and developed
films were scanned in CanoScan LiDE60 scanner.
Band intensity was quantified by ImageJ software. The obtained
images after scan were converted to 8-bit format in order to perform
uncalibrated optical density (OD).
Bands were selected and circumscribed with the rectangular ROI
selection and “Gels” function, followed by quantification of peak area
of obtained histograms. Data were acquired as arbitrary area values.
To ensure band intensity accurately reflects protein abundance,
this has been compared to one invariant normalization controls,
such as actin, as housekeeping proteins.
Furthermore, the linear range of detection of protein concentra-
tion, which can be used for reliable quantitation, has been deter-
mined by performing a dilution series of a representative
experimental sample (Fig EV1D).
Immunoprecipitation
200 lg to 1 mg of proteins was incubated O/N at 4°C on rotation
with 2 lg of Fbxw7 antibody (Bethyl, A301-721A). Rabbit IgG was
used as negative control. Protein G Agarose beads (Cell Signalling
#37478) were added for 2 h at 4°C on rotation. Precipitates were
washed three times with cold PBS before adding 2× loading buffer.
ª 2019 The Authors EMBO reports e46436 | 2019 17 of 22
Francesca Anna Carrieri et al EMBO reports
Published online: April 17, 2019 
Samples were denatured for 5 min at 95°C and then analysed by
Western blot.
Immunoprecipitation using GFP-Trap_A beads (ChromoTek)
was performed according to the manufacturer’s instructions.
Phos-tag gel
Prior loading into the gels for Phos-tag SDS–PAGE, samples were
supplemented with 10 mM MnCl2. Phos-tag SDS–PAGE was carried
out as previously described [62,86]. After electrophoresis, gels were
washed three times for 10 min each in the transfer buffer [48 mM
Tris/HCl, 39 mM glycine and 20% (v/v) methanol] containing
10 mM EDTA and 0.05% (w/v) SDS, followed by one wash in the
transfer buffer containing 0.05% SDS for 10 min. Proteins were
transferred and incubated with specific antibodies as previously
described.
Mass spectrometry
Upon separation by SDS–PAGE on NuPAGETM 4-12% Bis-Tris
protein gels (Thermo Scientific) and staining with Instant Blue
(Expedeon), protein bands were excised from gels. Samples were
reduced with 10 mM DTT at 50°C for 30 min and alkylated with
100 mM IAA at room temperature for 20 min in the dark.
Digestion was carried out by adding sequencing grade chymo-
trypsin (Sigma) at a ratio of 1–50 (enzyme to substrate) and incubat-
ing O/N at 30°C.
Peptides were extracted with 100% ACN containing 2.5% formic
acid and dried in a vacuum centrifuge.
Mass spectrometric analysis was performed by LC-MS-MS
using a linear ion trap-orbitrap hybrid mass spectrometer (LTQ-
Orbitrap Velos, Thermo Fisher Scientific) and coupled to a Dionex
Ultimate 3000 nanoLC system. Peptides were typically injected
onto a Thermo Scientific 15 cm Easy spray column (Part No.
ES800), with a flow of 300 nl/min and eluted over a 40 min
linear gradient of 97% solvent A (3% DMSO, 2% Acetonitrile,
0.1% formic acid in H2O) to 35% solvent B (90% acetonitrile,
3% DMSO, 0.08% formic acid in H2O). Data files were analysed
by Proteome Discoverer 2.0 (Thermo), using Mascot 2.4.1
(www.matrixscience.com), and searching against the Swissprot
and MRC-PPU (University of Dundee) databases. Scaffold (www.
ProteomeSoftware.com) was also used to examine the Mascot
result files. Allowance was made for the following modifications:
fixed, Carbamidomethyl (C), and variable, Oxidation (M), Dioxi-
dation (M) and Phosphorylation (S, T and Y). Error tolerances
were 10 ppm for MS1 and 0.6 Da for MS2. Phospho-sites were
assigned according to Proteome Discoverer ptmRS when the phos-
pho-RS site probability was ≥ 90%.
The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE [87] partner reposi-
tory with the dataset identifier PXD013038 and 10.6019/PXD013038.
Kinase assay
Kinase assay was designed and performed by MRC-PPU Interna-
tional centre for Kinase Profiling at University of Dundee (http://
www.kinase-screen.mrc.ac.uk/). All assays were carried out using a
radioactive (33P-ATP) filter-binding assay.
Fluorescence-activated cell sorter analysis
HEK293 cells were harvested, pelleted by gentle centrifugation
(450 g × 5 min) and washed once in 1 ml of PBS + 1% v/v FBS
and transferred to FACS tubes (Scientific Laboratory Supplies).
Cells were pelleted again and then fixed in cold 70% ethanol for
30 min at room temperature.
Cells number was adjusted to approximately 5 × 105 cells, and
then, cells were washed twice in PBS +1% v/v FBS.
Cell pellet was then resuspended in 300 ll of staining buffer
(50 lg/ml propidium iodide, 50 lg/ml RNase A in PBS +1% v/v
FBS) and incubated for 30 min in the dark at room temperature.
FACS analyses were conducted by flow cytometry and cell sort-
ing facility (University of Dundee).
Briefly, samples were analysed on a FACS Canto II flow
cytometer from Becton Dickinson. Propidium iodine was detected
using 488 nm excitation and emission collected at 587  40 nm.
Data were analysed using Flowjo software (Flowjo, LLC). Single
cells were identified on the basis of PI-A and PI-W measure-
ments and doublets excluded. Cell cycle distribution of the result-
ing PI-A histograms was determined using the Watson-Pragmatic
model.
Cell cycle synchronization
To synchronize HEK293 or HEK293T CDK2 KO cells at G1/S, a
double thymidine block assay was performed. Cells were treated
with 2.5 mM of thymidine (Sigma) for 18 h, washed twice with
PBS, released into fresh media for 9 h, treated for a further 14 h
with 2.5 mM of thymidine and then released again into fresh media
following two washes in PBS. Cells were then collected for FACS
and Western blot protein analyses at the indicated time points,
following protocols already described.
Immunofluorescence microscopy and image analysis
iPS cells (ChiPS4, Cellartis) were washed with PBS and fixed with
2% v/v paraformaldehyde (PFA) at room temperature for 20 min
and washed with PBST. Cells were permeabilized with 0.5% Triton
X-100 and 0.5% Tween-20 in PBS for 10 min and washed twice for
5 min with PBST and then for 5 min with PBS. Antigen retrieval
was performed using 1% v/v sodium dodecyl sulphate (SDS) for
7 min, followed by a 10-min incubation in PBS and 5-min PBST
washes. Coverslips were then blocked in blocking solution (0.5%
fish scale gelatine (FSG), 0.5% Triton X-100 and 0.5% Tween-20 in
PBS) for 90 min. Cells were incubated with Cleaved Notch 1 (Cell
Signalling #4147; 1:100) and Cyclin A (Santa Cruz #271645; 1:200)
primary antibodies. Control coverslips were left in the blocking
solution for the duration of the primary incubation. Following
primary antibody, cells were washed four times for 5 min each in
PBST and afterwards incubated in secondary AF488 Donkey anti-
rabbit (Abcam #21206) and AF647 Donkey anti-mouse (Invitrogen
#A31571) antibodies diluted 1:200 in block solution for 1 h at RT, in
dark. Cells were washed with PBST and then with PBS. To visualize
nucleotide incorporation during S phase, coverslips were incubated
in Click-iT EdU reaction mix with Azide 555 (Thermo Fisher Scien-
tific #C10338), following manufacturer’s protocol, for 30 min. Cells
were then stained with DAPI (1:1,000 from 1 mg/ml stock) for
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10 min at RT and mounted on Superfrost Plus microscope slides
(Thermo Scientific) with VectaShield.
Images were acquired using the Delta Vision “Mercury” deconvo-
lution microscope. An Olympus 60× oil immersion objective was
used, and images were captured using a CCD camera. Images were
deconvoluted and analysed using ImageJ (Fiji).
NICD intensity for each cell was measured within the cell, and
background mean grey intensity was also measured. Signal intensity
was calculated by subtracting the cell area multiplied by the mean
grey value of the background from the raw intermediate density
(RawIntDen) of the cell. Values of secondary antibody only incu-
bated cells were subtracted from the fully stained intensities to get
normalized intensity values. To confirm NICD signal was real, iPS
cells were treated with either 150 nM LY411575 or 1 lM MLN4924
or DMSO for 3 h. MLN4924 acted as an amplifier of NICD signal by
decreasing its degradation and served as positive control for NICD
signal and LY411575 served as a negative control, as it blocked
proteolytic cleavage of the intracellular Notch domain.
Mouse embryo explant culture
E10.5 CD1 mice embryos were harvested and explants were
prepared as previously described [88]. Each embryo’s posterior part
was divided into two halves by cutting along the neural tube. The
explants were cultured in hanging drops of culture medium
composed of DMEM/F12 (Gibco), 10% FBS, 1% penicillin–strepto-
mycin, 10 ng/ml Fgf2 (PeproTech).
One half was cultured in medium containing Purvalanol B
(1 lM) or RO-3306 (10 lM), whereas the control side was cultured
in normal medium (DMSO). Both sides were cultured for 4 h and
then analysed for expression of Lfng mRNA by in situ hybridization.
For the Western blot analysis, PSM explants from 5 embryos
were cultured in DMSO control vehicle and the corresponding
contralateral 5 PSM explants cultured in the presence of a small
molecule inhibitor.
Experiments were conducted in strict adherence to the Animals
(Scientific Procedures) Act of 1986 and UK Home Office Codes of
Practice for use of animals in scientific procedures.
In situ hybridization of PSM explants using exonic RNA probes
For whole-mount embryos and explants, in situ hybridization analy-
sis was performed with the use of exonic anti-sense RNA probes as
previously described [89].
Samples were imaged using a Leica bright field dissection micro-
scope using Volocity acquisition software. The number of somites
present in each explant (identical between explant pairs but variable
between embryos) was recorded.
To fix the tissue, samples were incubated for 2 h at RT in 4%
PFA/PBS, washed copiously in PBST and transferred into sealed
Eppendorf tubes containing 0.01% sodium azide/PBS for long-term
storage at 4°C.
Chicken culture and somite size analysis
Fertilized chick (Gallus gallus) embryos from Henry Stewart & Co
farm, Norfolk, UK, were incubated for approximately 40 h at 38°C
5% CO2 to yield embryos between Hamburger Hamilton (HH) stages
9–10 as judged by somite number and morphology. Whole chicken
embryos were cultured on filter papers with 1 lM of Purvalanol B or
10 lM of RO-3306 in culture media for 7.5 h. After fixation, embryos
were imaged and somite size recorded using ImageJ software.
We define bi,j to be the position of the j
th somite boundary in the
ith PSM sample where j = 0 represents the posterior-most boundary
in the embryo at the end of the experiment, j = 1 represents the
boundary anterior to that etc.
The length of the jth somite is defined to be:
Si;j ¼ bi;j  bi;j1; j ¼ 1; 2; 3; . . .
The ratio of successive somite lengths is given by:
ri;j ¼ Si;j
Si;jþ1
; j ¼ 1; 2; 3; . . .
The log2 fold change is given by:
log2ðri;jÞ; j ¼ 1; 2; 3; . . .
Samples (n = 14) were pooled based upon treatment protocol:
DMSO (i = 1,. . .,14), PurB, (i = 15,. . .,28), RO-3006, (i = 29,. . .,42).
The mean value at each somite index was computed together with
the standard error of the mean. Data at each somite position were
tested for deviation from normality using a Kolmogorov–Smirnov
test, and the null hypothesis was not rejected at the 5% significance
level. Paired t-tests were used to compare the effect of respective
treatments with control (DMSO treatment) at each somite position.
Statistical analysis
Unless indicated, statistical analyses were performed using
GraphPad software.
One-way ANOVA or Student’s t-tests were performed in all the
data comparing control to treatment conditions, with P values calcu-
lated as *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001. All experiments
have been performed at least three times.
Expanded View for this article is available online.
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